ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near San Francisco, CA, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

San Francisco, California, United States and 125 other locations

and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allog...

Enrolling
ACUTE MYELOID LEUKEMIA; AML
MYELODYSPLASTIC SYNDROME; MDS
Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)

Phase 1

Jasper Therapeutics

Stanford, California, United States and 5 other locations

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: ZN-c3
Drug: ZN-d5 ZN-c3

Phase 1, Phase 2

K-Group Alpha

San Francisco, California, United States and 12 other locations

the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML....

Enrolling
Acute Myeloid Leukemia
Biological: WU-NK-101

Phase 1

Wugen, Inc.

Palo Alto, California, United States and 8 other locations

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Palo Alto, California, United States and 33 other locations

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...

Enrolling
AML With Monocytic Differentiation
CMML
Biological: IO-202 and Azacitidine
Biological: IO-202

Phase 1

Immune-Onc Therapeutics

San Francisco, California, United States and 13 other locations

or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...

Enrolling
Acute Myeloid Leukemia
Drug: Quizartinib
Drug: Etoposide

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

San Francisco, California, United States and 36 other locations

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

San Francisco, California, United States and 73 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Stanford, California, United States and 222 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Oakland, California, United States and 43 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems